Azer-Cel (azercabtagene zapreleucel)

Open Label, Phase 1/1b Study in Relapsed/Refractory Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia

NOW RECRUITING IN THE USA & OPENING SOON IN AUS

*(NHL) Relapsed/Refractory Non-Hodgkin Lymphoma, (B-All) Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

onCARlytics (CF33 + CD19)

OASIS: Open Label, Phase 1 Study of CF33-CD19 in combination with blinatumomab in Mixed Advanced Solid Tumours

NOW RECRUITING IN THE USA

VAXINIA (CF33 + hNIS)

MAST: Open Label, Adaptive Phase 1 Study in Mixed Advanced Solid Tumours

NOW RECRUITING IN AUSTRALIA & USA

CHECKvacc (CF33 + hNIS + PD-L1)

Open Label, Phase 1 Investigator Sponsored Study in Triple Negative Breast Cancer

Neo-POLEM

Investigator Sponsored Study: Open Label, Phase 2 Study in Operable MSI-High Colorectal Cancer (CRC)

Recruitment Opening Soon IN the UK & AUS

PD1-Vaxx (PD-1)

IMPRINTER: Open Label, Phase 1 Study of PD1-Vaxx in Adults with Non-Small Cell Lung Cancer

HER-Vaxx (HER-2)

nextHERIZON: Open Label, Phase 2 Study of HER-Vaxx in combination with chemotherapy or pembrolizumab in metastatic gastric cancer after progression on trastuzumab

HERIZON: Open Label, Phase 1b/2 study of HER-Vaxx and Chemotherapy compared to Chemotherapy only in patients with HER-2 positive advanced Gastric Cancer.

Participation in Imugene clinical trials is always based on the patient’s own decision. For further information on how to participate in our clinical trials, please contact your treating physician.